Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a Surgical Aortic Valve Replacement (SAVR). The DurAVR™ valve was easy to manipulate and was able to be optimally positioned by the implanting surgeon in the aortic valve replacement procedures, promoting better results.